FDA declines Summit's lung cancer drug because it showed no significant survival gain

Summit Therapeutics said the agency's complete response letter found a delay in tumor progression was not enough without a statistically significant overall survival result.

Add FinanceInTime as a preferred source on Google
Illustration of a laboratory pipette over a tray of sample wells on a clean bench
Illustration. Not a photo of a real laboratory or trial.Illustration: FinanceInTime

The US Food and Drug Administration has declined to approve ivonescimab, the lung cancer drug from Summit Therapeutics (Nasdaq: SMMT), which Akeso invented, according to a company release dated November 15. Summit said it received a complete response letter, the document the agency sends when it will not approve an application as filed.

Progression-free survival was not enough on its own

The application covered ivonescimab combined with platinum-containing chemotherapy for adults with locally advanced or metastatic non-small cell lung cancer who had already been treated with an EGFR-targeted drug. Summit said the letter states that the application cannot be approved in its present form.

According to Summit, the FDA determined that substantial evidence of effectiveness is not established without a statistically significant improvement in overall survival, the length of time patients live. The agency also said the benefit in progression-free survival, the time before the cancer worsens, does not support a positive benefit-risk profile when overall survival is not significantly better. Summit said the HARMONi trial met its progression-free survival primary endpoint.

What Summit says the survival data show

Summit said the trial's primary overall survival analysis showed a positive trend without reaching statistical significance. In a post-hoc analysis, longer-term follow-up of Western patients showed what Summit called a consistent overall survival benefit, with a hazard ratio of 0.76 in the full population. A post-hoc analysis is one run after the trial's planned analyses, so it does not replace the primary result. A hazard ratio below 1.0 means a lower risk of death in the ivonescimab arm.

On safety, Summit reported that 16 patients (7.3%) discontinued ivonescimab because of treatment-related events, against 11 patients (5.0%) on placebo. Treatment-related deaths occurred in four patients (1.8%) in the ivonescimab plus chemotherapy arm and five patients (2.3%) in the chemotherapy-alone arm.

The company's response and what remains

Robert W. Duggan, Summit's chairman and co-chief executive, said: "We are disappointed for patients and their families awaiting additional treatment options in this setting." He added that with five positive Phase III studies between Summit and Akeso, "nothing changes" for the wider program.

Summit said ivonescimab was first approved for marketing in China in May 2024 and is not approved by any regulatory authority in Summit's license territories, including the United States and Europe. The company listed continuing Phase III trials in first-line lung cancer and colorectal cancer, among other studies. The release did not say whether Summit will resubmit the application or what the FDA asked for, and it did not give a timeline.

A rejected first filing leaves the pipeline to carry the company

We think this decision moves the weight of Summit's story from one application to the trials still running. A company with no approved product depends on its financing and its next readouts, and the first-line lung cancer studies the company lists are now the evidence that matters most. The opportunity is that a larger trial designed around overall survival could answer the question the FDA raised; the threat is that the same endpoint could again fall short of significance.

We would weigh cash runway and the timing of those readouts over any single regulatory date, and we expect the company to be asked how it will fund the program if approval slips. Our view would change if Summit disclosed a clear agreement with the FDA on a path to resubmission.

The view in this final section is FinanceInTime's editorial opinion, for information only. It is not investment, tax, legal or other advice, and it does not take your circumstances into account. Forecasts are uncertain and past results do not guarantee future ones.

Sources

  1. Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application — Summit TherapeuticsPrimary source
Add FinanceInTime as a preferred source on Google

More in Business

View All Business

Get Finance News in Your Inbox

Daily headlines, market insights and analysis from our editors.